A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
Clinical trial NCT06962267 · RECRUITING
Trial details
- NCT number
- NCT06962267
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-18
- Primary completion
- 2027-08-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.